POCKET GUIDE. Pocket Guide. Cardiometabolic Health Congress. October 2 5, 2013 Sheraton Hotel Boston, MA.

Transcription

1 2013 Cardiometabolic Health Congress October 2 5, 2013 Sheraton Hotel Boston, MA Pocket Guide POCKET GUIDE Pocket Guide Sponsor

2 Visit to learn more about this FDA-approved therapy. For any questions, please call VIVUS Medical Information at VIVUS, Inc. All rights reserved USP

3 2013 Table of Contents Welcome Message...4 Hours of Operation...5 Floor Plan....5 Schedule-at-a-Glance...6 Program Overview Accreditation Chairpersons Distinguished Faculty Agenda Industry Supporters & Sponsors Association Supporters Exhibitors Guide Publication Supporters Table of Contents 3

4 2013 WELCOME! Welcome to the 8th Annual Cardiometabolic Health Congress (CMHC). We are pleased you have joined us, our world-renowned expert faculty, 42 prestigious medical associations, and your peers to combat the global health crisis emanating from cardiovascular and metabolic disease. It is impossible to separate cardiovascular from metabolic disease when it comes to risk assessment, prevention, and clinical intervention. No other conference addresses the breadth and depth of this new paradigm like the CMHC translating the most current clinical information into real-world solutions that will undoubtedly make a significant impact on your daily practice. Enclosed you will find the CMHC schedule-at-a-glance and detailed agenda, as well as information on our distinguished faculty and corporate-supported and sponsored symposia. Should you require assistance during your stay, please do not hesitate to visit the CMHC Registration Desk located on the Second Floor of the Sheraton Boston Hotel. Enjoy your stay in Boston! Warm regards, George L. Bakris, MD University of Chicago Pritzker School of Medicine Robert H. Eckel, MD University of Colorado Anschutz Medical Campus Christie M. Ballantyne, MD Methodist DeBakey Heart Center Baylor College of Medicine Jay S. Skyler, MD, MACP University of Miami Miller School of Medicine 4

5 2013 Cardiometabolic Health Congress Hours of Operation Registration Desk - Second Floor - Sheraton Hotel Wednesday, October 2 Thursday, October 3 Friday, October 4 Saturday, October 5 10:00am 8:00pm 6:00am 6:00pm 6:00am 6:00pm 6:00am 12:30pm Exhibit Hall - Hynes Convention Center Thursday, October 3 Friday, October 4 9:30am 12:00pm 2:30pm 6:45pm 9:00am 12:00pm 2:00pm 5:00pm Welcome Reception - Exhibit Hall (Hynes Convention Center) Thursday, October 3 5:30pm 6:30pm Sheraton Hotel Second Floor To Hynes Convention Center Hours of Operation CMHC Registration 5

6 Schedule-at-a-Glance Wednesday, October 2, :00pm - 1:30pm Lunch Symposium (non-cme)* Republic Ballroom 1:30pm - 2:45pm Afternoon Symposium (non-cme)* Constitution Ballroom 2:45pm - 4:00pm Afternoon Symposium (non-cme)* Back Bay Ballroom 2:45pm - 4:00pm Afternoon Symposium (non-cme)* Grand Ballroom 4:00pm - 5:15pm Afternoon Symposium* Republic Ballroom 5:15pm - 6:45pm Early Evening Symposium (non-cme)* Constitution Ballroom 7:00pm - 8:30pm Dinner Symposium (non-cme)* Back Bay Ballroom 7:00pm - 8:30pm Dinner Symposium (non-cme)* Grand Ballroom Thursday, October 3, 2013 Schedule-at-a-Glance 6:15am - 7:45am Breakfast Symposium* Back Bay Ballroom 6:15am - 7:45am Breakfast Symposium* Constitution Ballroom 8:00am - 10:00am General Session Grand Ballroom 10:00am - 11:00am Exhibit Hall Break Hynes Convention Center 11:00am - 12:00pm General Session Grand Ballroom 12:15pm - 1:45pm Lunch Symposium* Republic Ballroom 12:15pm - 1:45pm Lunch Symposium* Back Bay Ballroom 12:15pm - 1:45pm Lunch Symposium* Constitution Ballroom 2:00pm - 3:30pm General Session Grand Ballroom 3:30pm - 4:15pm Exhibit Hall Break Hynes Convention Center 4:15pm - 5:15pm General Session Grand Ballroom 5:30pm - 6:30pm Welcome Reception Hynes Convention Center 7:00pm - 9:00pm Dinner Symposium* Back Bay Ballroom 7:00pm - 9:00pm Dinner Symposium* Constitution Ballroom * Pre-registration is required to attend these sessions. 6

7 Friday, October 4, :15am - 7:45am Breakfast Symposium* Back Bay Ballroom 6:15am - 7:45am Breakfast Symposium* Constitution Ballroom 8:00am - 9:50am General Session Grand Ballroom 9:50am - 10:50am Exhibit Hall Break Hynes Convention Center 10:50am - 12:15pm General Session Grand Ballroom 12:30pm - 2:00pm Lunch Symposium* Constitution Ballroom 12:30pm - 2:00pm Lunch Symposium* Back Bay Ballroom 2:15pm - 3:15pm General Session Grand Ballroom 3:15pm - 4:00pm Exhibit Hall Break Hynes Convention Center 4:00pm - 5:30pm General Session Grand Ballroom 6:30pm - 8:30pm Dinner Symposium* Constitution Ballroom 6:30pm - 8:30pm Dinner Symposium* Back Bay Ballroom Saturday, October 5, :15am - 7:45am Breakfast Symposium* Constitution Ballroom 8:00am - 12:30pm General Session Grand Ballroom * Pre-registration is required to attend these sessions. Stay Connected with the CMHC Facebook.com/CardiometabolicHealth Cardiometabolic Health Congress Twitter.com/CMHC_CME Schedule-at-a-Glance Blog.cardiometabolichealth.org 7

8 Program Overview Program Overview 8 Statement of Need* The ever-increasing presence of cardiometabolic risk continues to be a major challenge for health care professionals in the United States. The prevalence of most cardiometabolic risk factors especially hypertension, diabetes, and obesity continues to rise. In the years ahead, American physicians should expect to treat unprecedented numbers of patients at high risk for morbidity and mortality from cardiovascular disease. In 2000, approximately 32% of U.S. adults had the metabolic syndrome, a constellation of cardiometabolic risk factors including excessive abdominal fat, insulin resistance, dyslipidemia, and hypertension. Today, that figure has climbed to 34% and may even be as high as 38%, depending on the criteria used to define the syndrome. Cardiometabolic Risk Factors Are Undertreated and Difficult to Manage Despite the well-documented risks of unchecked diabetes, obesity, hypertension, and dyslipidemia, these conditions are commonly undertreated. Even when treated, they remain stubbornly difficult to manage. Half or more of treated patients with diabetes fail to meet recommended target HbA1c goals. Analyses of data from National Health and Nutrition Examination surveys found that only one-half to one-third of treated patients achieve the American Diabetes Association s recommended HbA1c target of 7% or less. In addition, a report released by the American Association of Clinical Endocrinologists stated that two out of three patients with type 2 diabetes were not achieving the Association s recommended HbA1c goal of 6.5% or less. When it comes to first-line therapy for obesity diet and exercise few patients succeed, and any improvements are usually modest. Current pharmacotherapy options are limited. Available obesity drugs have, to date, produced only modest weight loss in most patients and have been linked to adverse gastrointestinal effects and mood disorders. Furthermore, many clinicians do not address diet and exercise for weight loss with their patients, citing a lack of belief that lifestyle changes can work, lack of understanding of how to counsel patients about lifestyle change, and inadequate amounts of time and personnel. Only 71% of patients with hypertension are receiving any form of treatment. Of these, less than half (48%) have their blood pressure under control; hypertension remains uncontrolled in 52% of treated patients. Less than half of those who qualify for any kind of lipid-modifying treatment to reduce their risk of coronary heart disease are receiving it. In fact, less than half of even the highest-risk individuals those with symptomatic coronary heart disease are receiving lipid-lowering treatment. Of those being treated, only about one-third are achieving target goals.

9 Conclusion Healthcare professionals play a major role in stemming the future burden of cardiovascular disease, diabetes, and associated comorbidities by employing aggressive strategies for the early identification and comprehensive management of patients presenting with multiple cardiometabolic risk factors. The 2013 Cardiometabolic Health Congress will translate the latest cutting-edge medical research into practical, clinical approaches for preventing, delaying, and managing cardiovascular and metabolic risk. The goal is to provide the medical community with evidence-based interventions to improve health outcomes and quality of life for the growing numbers of patients at increased cardiometabolic risk. Purpose Statement The goal of the Congress is to improve patient outcomes through early identification and intervention strategies for patients with, or at risk of developing, diabetes and vascular disease. Target Audience & Learning Objectives The CMHC is designed for advanced-level clinicians responsible for the prevention, diagnosis, and management of cardiometabolic risk. At the end of the Congress, participants will be able to: Explain the interrelationships among the various cardiometabolic risk factors, their impact on cardiovascular health, and their common comorbidities. Translate evidence-based strategies for prevention, screening, and treatment of cardiometabolic risk factors and their comorbidities to their clinical practice. Identify which interventions, including lifestyle changes and various drugs in combination, are most appropriate for particular patients based on their risk profiles. Identify how novel and emerging therapies can be integrated into clinical practice to reduce morbidity and mortality from cardiovascular and metabolic disease. * To access the 2013 CMHC full statement of need and reference list, please visit Program Overview 9

10 Accreditation Earn CME Credits Physician Accreditation This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medical Education Resources and HealthScience Media, Inc. Medical Education Resources is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation Medical Education Resources designates this live activity for a maximum of AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. AAFP American Academy of Family Physicians This live activity, 2013 Cardiometabolic Health Congress, with a beginning date of October 2, 2013, has been reviewed and is acceptable for up to Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity. AANP American Academy of Nurse Practitioners This program is approved for contact hours of continuing education (which includes hours of pharmacology) by the American Association of Nurse Practitioners. Program ID Accreditation ANCC Nursing Accreditation Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center s Commission on Accreditation. This CE activity provides contact hours of continuing nursing education. Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for contact hours. Registered Dietitian Accreditation Medical Education Resources (Provider Number ME110) is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive continuing professional education units (CPEUs) for completion of this program/material. 10

11 Pharmacy Accreditation Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for contact hours (2.775 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Program Number L01-P) There is a registration fee for this educational activity. This activity is certified as Knowledge based CPE. Attention Certified Diabetes Educators: The 2013 Cardiometabolic Health Congress (CMHC) is accredited by Medical Education Resources (MER). MER is accredited by the ACCME, ANCC, ACPE, and the CDR to provide continuing medical education. All of these accredited organizations are recognized by the AADE when applying for CDE renewal of certification or for initial certification Disclosure of Conflicts of Interest It is the policy of Medical Education Resources to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest. How to Obtain Your CE Credit To obtain CE credit, please return your completed 2013 Cardiometabolic Health Congress evaluation form to HealthScience Media, Inc. On-site: Please return your completed evaluation form in the evaluation drop box outside the general session room. Post-conference: Please fax your completed evaluation form to Evaluation forms must be received by November 8, Forms received after this date will not be accepted. No exceptions. Certificates will be mailed directly to the address indicated on your evaluation form within ten (10) weeks of the date of submission. Accreditation 11

12 Chairpersons George L. Bakris, MD Professor of Medicine Director, ASH Comprehensive Hypertension Center University of Chicago Medicine Pritzker School of Medicine Christie M. Ballantyne, MD Professor of Medicine Chief, Section of Cardiovascular Research Chief, Section of Cardiology Department of Medicine, Baylor College of Medicine Director, Center for Cardiovascular Disease Prevention Baylor College of Medicine Methodist DeBakey Heart Center Robert H. Eckel, MD Professor of Medicine Division of Endocrinology, Metabolism and Diabetes Professor of Physiology and Biophysics Charles A. Boettcher II Chair in Atherosclerosis Director, Discovery Translation Colorado Clinical & Translational Science Institute University of Colorado Anschutz Medical Campus Director, Lipid Clinic, University Hospital Distinguished Faculty Rajiv Agarwal, MD Professor of Medicine Indiana University School of Medicine Jay S. Skyler, MD, MACP Professor of Medicine, Pediatrics, and Psychology Division of Endocrinology, Diabetes and Metabolism University of Miami Miller School of Medicine Deputy Director for Clinical and Academic Programs Diabetes Research Institute Caroline Apovian, MD Professor of Medicine Boston University School of Medicine Director Center for Nutrition and Weight Management Boston Medical Center Louis Aronne, MD Dir., Comprehensive Weight Control Program New York-Presbyterian Hospital Clinical Professor of Medicine Weill-Cornell Medical College Harold Bays, MD Medical Director/President Louisville Metabolic and Atherosclerosis Research Center, Inc. Distinguished Faculty David S. H. Bell, MB Clinical Professor of Medicine University of Alabama Medical School Director Southside Endocrinology Thomas Blevins, MD Chief of Endocrinology Seton Hospital & St. David s Medical Center Director Texas Diabetes & Endocrinology Robert Brook, MD Associate Professor of Medicine Division of Cardiovascular Medicine University of Michigan Robert Busch, MD Endocrinologist The Endocrine Group Deepak L. Bhatt, MD, MPH Chief of Cardiology VA Boston Healthcare System Dir., Integrated Interventional CV Program Brigham and Women s Hospital Senior Investigator, TIMI Study Group Professor, Harvard Medical School Eliot Brinton, MD Director of the Metabolism Section of Cardiovascular Genetics Associate Professor University of Utah School of Medicine Matthew Budoff, MD Professor of Medicine David Geffen School of Medicine Program Director, Cardiology Harbor-UCLA Medical Center John Buse, MD Verne S. Caviness Distinguished Professor Chief, Division of Endocrinology Director, Diabetes Care Center Executive Associate Dean, Clinical Research Univ. of North Carolina School of Medicine 12 Sonia Caprio, MD Professor Yale School of Medicine Pediatric Endocrinologist Yale Medical Group Glenn Chertow, MD Norman S. Coplon/Satellite Healthcare Professor of Medicine Chief, Division of Nephrology Stanford University School of Medicine

13 Distinguished Faculty Robert Chilton, DO Professor of Medicine Director, Cardiac Catheterization Lab University of Texas Health Science Center William Cushman, MD Prof. of Preventive Medicine and Medicine University of Tennessee Health Science Ctr. in Memphis Chief, Preventive Medicine Veterans Affairs Medical Center in Memphis Samuel Dagogo-Jack, MD Professor of Medicine Director, Division of Endocrinology, Diabetes & Metabolism A. C. Mullins Chair in Translational Research University of Tennessee Health Science Center Paresh Dandona, MD Founder, Diabetes-Endocrinology Center of WNY Kaleida Health Chief, Division of Endocrinology Distinguished Professor of Medicine State University of New York at Buffalo P. Barton Duell, MD Director, Lipid-Atherosclerosis Laboratory Director, Lipid Disorders Clinic Division of Endocrinology, Diabetes & Clinical Nutrition Oregon Health and Science University Sergio Fazio, MD Cornelius Vanderbilt Professor of Medicine Professor of Pathology, Immunology & Microbiology Chief, Cardiovascular Disease Prevention Vanderbilt University Medical Center Keith C. Ferdinand, MD Professor of Clinical Medicine Tulane University School of Medicine Chair, National Forum for Heart Disease & Stroke Prevention Vivian Fonseca, MD Professor of Medicine and Pharmacology Tullis Tulane Alumni Chair in Diabetes Chief, Section of Endocrinology Tulane University Health Sciences Center JoAnne Foody, MD Medical Director Cardiovascular Wellness Program Brigham and Women s Hospital Associate Professor Harvard Medical School Ken Fujioka, MD Director, Nutrition & Metabolic Research Director, Center for Weight Management Department of Endocrinology Scripps Clinic W. Timothy Garvey, MD Butterworth Professor and Chair Department of Nutrition Science University of Alabama at Birmingham GRECC Investigator & Staff Physician Birmingham VA Medical Center Dir., UAB Diabetes Research Center Thomas Giles, MD Clinical Professor of Medicine Heart and Vascular Institute Tulane University School of Medicine Irl Hirsch, MD Professor of Medicine Division of Metabolism, Endocrinology & Nutrition Univ. of Washington School of Medicine Peter Jones, MD Associate Professor of Medicine Ctr. for Cardiovascular Disease Prevention Methodist DeBakey Heart and Vascular Ctr. Baylor College of Medicine J. Michael Gaziano, MD Scientific Dir., Massachusetts Veterans Epidemiology Research & Information Ctr. VA Boston Healthcare System Chief, Division of Aging Brigham and Women s Hospital Prof. of Medicine, Harvard Medical School Robert Harrington, MD Arthur L. Bloomfield Professor of Medicine Chair, Department of Medicine Stanford University Terry Jacobson, MD Professor of Medicine, Emory University Director, Office of Health Promotion & Disease Prevention Co-Dir., Lipid & CV Risk Reduction Program Grady Health Systems C. Ronald Kahn, MD Mary K. Iacocca Professor Harvard Medical School Chief Academic Officer Joslin Diabetes Center Distinguished Faculty Lee M. Kaplan, MD Associate Professor of Medicine Harvard Medical School Director, Obesity, Metabolism & Nutrition Institute Massachusetts General Hospital Samuel Klein, MD William H. Danforth Professor of Medicine and Nutritional Science Chief, Division of Geriatrics and Nutritional Sciences Director, Center for Human Nutrition Washington University School of Medicine 13

14 Distinguished Faculty Mikhail Kosiborod, MD Clinical Associate Professor University of Missouri Kansas City Cardiologist Saint Luke s Hospital of Kansas City I-Min Lee, MD, ScD Prof. of Medicine, Harvard Medical School Prof. of Epidemiology Harvard School of Public Health Associate Epidemiologist Brigham and Women s Hospital Robert Kushner, MD Professor of Medicine Division of General Internal Medicine Northwestern University Feinberg School of Medicine Clinical Director, Northwestern Comprehensive Center on Obesity Peter Libby, MD Chief, Cardiovascular Medicine Brigham and Women s Hospital Mallinckrodt Professor of Medicine Harvard Medical School David Ludwig, MD Director, New Balance Foundation Obesity Prevention Center Director, Optimal Weight for Life Clinic Boston Children s Hospital Prof., Pediatrics, Harvard Medical School Prof., Nutrition, Harvard School of Public Health Darren McGuire, MD Professor of Medicine University of Texas Southwestern Medical Center Barbara Millen, DrPH, RD President Millennium Prevention, Inc. Director Boston Nutrition Foundation, Inc. Peter McCullough, MD Consultant Cardiologist Chief, Division of Nutrition & Preventive Medicine William Beaumont Hospital Clinical Professor of Health Science Oakland University William Beaumont School of Medicine Luigi Meneghini, MD Professor of Clinical Medicine Division of Endocrinology, Diabetes & Metabolism Director, Kosow Diabetes Treatment Center Diabetes Research Institute Univ. of Miami Miller School of Medicine Patrick Moriarty, MD Director Atherosclerosis/LDL-Apheresis Center Professor of Medicine University of Kansas Medical Center Distinguished Faculty David Morrow, MD Dir., Levine Cardiac Intensive Care Unit Cardiovascular Division Brigham and Women s Hospital Senior Investigator, TIMI Study Group Associate Professor Harvard Medical School David Nathan, MD Director Diabetes Center and Clinical Research Ctr. Massachusetts General Hospital Professor of Medicine Harvard Medical School Anne Peters, MD Professor, Keck School of Medicine Director, Clinical Diabetes Programs University of Southern California Richard Pratley, MD Dir., Florida Hospital Diabetes Institute Sr., Scientist, Translational Research Institute for Metabolism and Diabetes Professor, Sanford Burnham Medical Research Institute Sunder Mudaliar, MD Staff Physician VA San Diego Healthcare System Clinical Professor of Medicine University of California, San Diego E. Magnus Ohman, MD Professor of Medicine The Kent and Siri Rawson Director Duke Prgm. for Advanced Coronary Disease Associate Director, Duke Heart Center Duke University Medical Center Jorge Plutzky, MD Director Vascular Disease Prevention Prgm/Lipid Clinic Co-Director, Preventive Cardiology Cardiovascular Division Brigham and Women s Hospital Gary Puckrein, PhD President and Chief Executive Officer National Minority Quality Forum 14 Daniel Rader, MD Cooper-McClure Prof. of Medicine & Pharmacology Chief, Division of Translational Medicine & Human Genetics Perelman School of Medicine, Univ. of Pennsylvania Associate Director, Penn s Institute for Translational Medicine & Therapeutics Paul Ridker, MD Director, Center for Cardiovascular Disease Prevention Brigham and Women s Hospital Eugene Braunwald Professor of Medicine Harvard Medical School

15 Distinguished Faculty Francesco Rubino, MD Catholic University of Rome Italy Marc Sabatine, MD Chairman, TIMI Study Group Associate Physician in CV Medicine Brigham and Women s Hospital Associate Professor of Medicine Harvard Medical School Benjamin Scirica, MD Attending Cardiologist Brigham and Women s Hospital Assistant Professor of Medicine Harvard Medical School Investigator, TIMI Study Group Arya Sharma, MD Professor of Medicine Chair, Obesity Research & Management University of Alberta Clinical Co-Chair, Alberta Health Services Obesity Program Daniel Simon, MD Dir., Harrington Heart & Vascular Institute Chief, Div. of Cardiovascular Medicine University Hospitals Case Medical Center Herman K. Hellerstein Professor of Cardiovascular Research Case Western Reserve University Laurence Sperling, MD Professor of Medicine in Cardiology Director The Center for Heart Disease Prevention Emory University School of Medicine Steven Smith, MD Scientific Director Translational Research Institute Professor Sanford Burnham Medical Research Institute Evan Stein, MD, PhD Voluntary Professor Laboratory Medicine University of Cincinnati Medical Center Jean-Claude Tardif, MD Director, Montreal Heart Institute Research Centre Professor of Medicine University of Montreal Peter Toth, MD Sterling Rock Falls Clinic Director of Preventive Cardiology Clinical Associate Professor Dept. of Family and Community Medicine Univ. of Illinois and Southern Illinois Univ. Chief of Medicine, CGH Medical Center Raymond Townsend, MD Professor of Medicine Director, Hypertension Program University of Pennsylvania Tracy Wang, MD Associate Professor of Medicine in Cardiology Duke University William White, MD Professor Univ. of Connecticut School of Medicine Chief, Division of Hypertension & Clinical Pharmacology Calhoun Cardiology Center University of Connecticut Health Center Bernard Zinman, MD Director Leadership Sinai Center for Diabetes Mount Sinai Hospital Professor of Medicine University of Toronto Sotirios Tsimikas, MD Professor of Medicine Director of Vascular Medicine Division of Cardiovascular Diseases, Department of Medicine University of California, San Diego Michael Weber, MD Professor of Medicine State University of New York Downstate College of Medicine Carol Wysham, MD Clinical Associate Professor of Medicine University of Washington-School of Medicine Section Head, Rockwood Center for Diabetes and Endocrinology Distinguished Faculty Collaborate with our expert faculty to decipher the most recent clinical data & the immediate implications for your patients & practice. 15

16 Agenda Wednesday, October 2, :00 1:30pm Lunch Symposium (non-cme) Consider the Role of the Kidney in Type 2 Diabetes Mellitus David S. H. Bell, MB Sponsored by Janssen Pharmaceuticals, Inc. 1:30 2:45pm Afternoon Symposium (non-cme) A Novel Treatment Option for Chronic Weight Management Robert Chilton, DO Sponsored by Eisai, Inc. 2:45 4:00pm Afternoon Symposium (non-cme) AZOR and TRIBENZOR : Fixed-Dose Combination Therapy Robert Busch, MD Sponsored by Daiichi Sankyo, Inc. 2:45 4:00pm Afternoon Symposium (non-cme) The Role of the Kidney in T2DM Pathophysiology Paresh Dandona, MD Sponsored by Bristol-Myers Squibb and AstraZeneca LP 4:00 5:15pm Afternoon Symposium Cardiometabolic Risk in Racial/Ethnic Minorities: Unique Aspects and Practical Solutions Keith C. Ferdinand, MD; JoAnne Foody, MD; Gary Puckrein, PhD; Laurence Sperling, MD; Tracy Wang, MD Sponsored by the American College of Cardiology in collaboration with the National Minority Quality Forum and the Association of Black Cardiologists 5:15 6:45pm Early Evening Symposium (non-cme) Advancements in Cardiometabolic Risk Assessment: Expert Analysis of Recent Evidence and Outcomes Eliot Brinton, MD; Peter McCullough, MD; Peter Toth, MD Sponsored by Atherotech Diagnostics Lab Agenda 7:00 8:30pm Dinner Symposium (non-cme) Chronic Management of Obesity: The Role of a Unique, Once-Daily Treatment W. Timothy Garvey, MD Sponsored by VIVUS, Inc. 7:00 8:30pm Dinner Symposium (non-cme) KYNAMRO (mipomersen sodium) injection: An Overview for Clinicians Sotirios Tsimikas, MD Sponsored by Genzyme, A SANOFI COMPANY Agenda and faculty are subject to change. 16

17 Thursday, October 3, :15 7:45am Breakfast Symposium State-of-the-Art Antiplatelet Therapy for Patients with ACS: Expert Analysis & Evidence-Based Guidelines for Optimizing Patient Outcomes Deepak L. Bhatt, MD, MPH; Robert Harrington, MD; E. Magnus Ohman, MD; Marc Sabatine, MD Supported by an educational grant from AstraZeneca 6:15 7:45am Breakfast Symposium New Strategies for Obesity Management & Cardiometabolic Risk Reduction: Expert Perspectives on Novel Therapies Targeting the CNS Louis Aronne, MD; Harold Bays, MD; Lee M. Kaplan, MD; Steven Smith, MD Supported by an educational grant from Eisai, Inc. 8:00 8:10am Opening Remarks Christie Ballantyne, MD 8:10 8:50am Keynote Session Inflammation & Cardiometabolic Risk Peter Libby, MD 8:50 10:00am Late-Breaking Clinical Trials & FDA Update Gain expert insight & perspective on how the most recent clinical trial data & FDA decisions will impact your daily practice moderator: Christie Ballantyne, MD discussants: Deepak L. Bhatt, MD, MPH; Robert Eckel, MD; Keith C. Ferdinand, MD; Jay Skyler, MD 10:00 11:00am Morning Break/Exhibit Hall Sponsored by Takeda Pharmaceuticals U.S.A., Inc. 11:00am 12:00pm Hot Topics in ACS: Debate moderator: Deepak L. Bhatt, MD, MPH discussants: Robert Harrington, MD; Daniel Simon, MD Customize your CMHC learning experience with our unique mix of plenary presentations, interactive panel discussions and challenging case study sessions. Agenda 17

18 Agenda Thursday, October 3, 2013 (cont d) 12:15 1:45pm Lunch Symposium Triglyceride & Mixed Dyslipidemia Management: Expert Analysis of Cutting-Edge Data & Evidence-Based Recommendations for Reducing Residual CV Risk Christie Ballantyne, MD; Harold Bays, MD; Deepak L. Bhatt, MD, MPH; Sergio Fazio, MD; Terry Jacobson, MD Supported by an educational grant from Amarin Pharma, Inc. 12:15 1:45pm Lunch Symposium Alternate Pathways for the Management of Type 2 Diabetes: Expert Analysis on Targeting Dopamine & the CNS for Glycemic Control & CV Risk Reduction David S. H. Bell, MB; Samuel Dagogo-Jack, MD; J. Michael Gaziano, MD; Jay Skyler, MD Supported by an educational grant from Santarus, Inc. 12:15 1:45pm Lunch Symposium Personalized SIHD Management: Evidence-Based Decision Making for Patients at Increased Cardiometabolic Risk JoAnne Foody, MD; Robert Harrington, MD; Mikhail Kosiborod, MD; David Morrow, MD Supported by an independent educational grant from Gilead Sciences, Inc. 2:00 2:45pm Keynote Session Translating Insights from Human Genetics into Novel Therapies for Dyslipidemia Daniel Rader, MD 2:45 3:30pm Biomarkers vs. Imaging for CV Risk Assessment and Treatment: Debate moderator: Christie Ballantyne, MD discussants: Matthew Budoff, MD; Paul Ridker, MD 3:30 4:15pm Afternoon Break/Exhibit Hall Agenda 4:15 5:15pm Clinical Controversies in Lipid Management: Case-Based Presentations & Discussion moderator: Christie Ballantyne, MD presenters: Harold Bays, MD; Robert Eckel, MD; JoAnne Foody, MD 5:15pm Closing Remarks Christie Ballantyne, MD 5:30 6:30pm Welcome Reception Agenda and faculty are subject to change. 18

19 Thursday, October 3, 2013 (cont d) 7:00 9:00pm Dinner Symposium The Next-Generation of Weight-Loss Medications: Expert Recommendations for Managing Obesity, Diabetes & Cardiometabolic Risk Robert Eckel, MD; W. Timothy Garvey, MD; Samuel Klein, MD; Robert Kushner, MD; Arya Sharma, MD Supported by an educational grant from VIVUS, Inc. 7:00 9:00pm Dinner Symposium Personalized T2DM Management: The Role of Incretin Therapies Along the Continuum of Care Robert Chilton, DO; Richard Pratley, MD; Benjamin Scirica, MD; Carol Wysham, MD This activity is supported by an independent medical education grant from Bristol-Myers Squibb and AstraZeneca LP Friday, October 4, :15 7:45am Breakfast Symposium Next-Generation Vasodilating Beta Blockers Along the HTN Continuum of Care: Expert Recommendations for Targeting Endothelial Dysfunction, BP and Cardiometabolic Risk George Bakris, MD; Keith C. Ferdinand, MD; Thomas Giles, MD; Michael Weber, MD Supported by an educational grant from Forest Laboratories, Inc. 6:15 7:45am Breakfast Symposium State-of-the-Art Management of Severe and Familial Hypercholesterolemia: Examining the Role of Antisense Therapy in Clinical Practice P. Barton Duell, MD; Peter Jones, MD; Patrick Moriarty, MD; Evan Stein, MD Supported by an educational grant from Genzyme, A SANOFI COMPANY 8:00 8:10am Opening Remarks Jay Skyler, MD 8:10 8:40am Personalized Diabetes Management: Selecting the Right Therapy John Buse, MD 8:40 9:10am Insulin Therapy: The State-of-the-Science Irl Hirsch, MD 9:10 9:50am T1DM 2013: Translating the Latest Advances into Clinical Practice Robert Eckel, MD; Jay Skyler, MD 9:50 10:50am Morning Break/Exhibit Hall Agenda 10:50 11:30am Pediatric Obesity & T2DM moderator: Jay Skyler, MD presenters: Sonia Caprio, MD; David Ludwig, MD 19

20 Agenda Friday, October 4, 2013 (cont d) 11:30am 12:15pm Diabetes Panel Discussion & Audience Q&A moderator: Jay Skyler, MD discussants: John Buse, MD; Sonia Caprio, MD; Robert Eckel, MD; Irl Hirsch, MD; David Ludwig, MD 12:30 2:00pm Lunch Symposium Advances in Basal Insulin Therapy: Expert Analysis of Novel Formulations, Combination Therapies & Delivery Technologies John Buse, MD; Irl Hirsch, MD; Luigi Meneghini, MD; Bernard Zinman, MD Supported by an educational grant from Novo Nordisk, Inc. 12:30 2:00pm Lunch Symposium Getting to the Heart of Diabetic Dyslipidemia in High-Risk Patients: Clinical Dilemmas & Novel Approaches to Cardiovascular Risk Reduction Darren McGuire, MD; Sunder Mudaliar, MD; Jorge Plutzky, MD; Jean-Claude Tardif, MD Supported by an educational grant from Genentech, A Member of the Roche Group 2:15 2:45pm Elevated Serum Creatinine: Different Meaning in Different Settings? George Bakris, MD 2:45 3:15pm CKD Endpoints in Clinical Trials: Guidance for Clinical Practice Glenn Chertow, MD 3:15 4:00pm Afternoon Break/Exhibit Hall 4:00 4:30pm Alternative Therapies for HTN: Examining the Evidence Robert Brook, MD 4:30 5:30pm Clinical Controversies in HTN Management: Expert Perspectives & Discussion moderator: George Bakris, MD discussants: Rajiv Agarwal, MD; Raymond Townsend, MD; William White, MD 5:30pm Closing Remarks George Bakris, MD Agenda 20 6:30 8:30pm Dinner Symposium Obesity Management 2013: Expert Perspectives on the Clinical Impact of Novel & Emerging Therapies Caroline Apovian, MD; Robert Eckel, MD; Ken Fujioka, MD; Robert Kushner, MD Supported by an educational grant from Novo Nordisk, Inc. 6:30 8:30pm Dinner Symposium CV Outcomes for Oral & Incretin-Based Therapies: Examining Cutting-Edge Data & Clinical Implications for Patient Care George Bakris, MD; William Cushman, MD; Vivian Fonseca, MD; William White, MD This activity is supported by an educational grant from Takeda Pharmaceuticals International, Inc., US Region

21 Saturday, October 5, :15 7:45am Breakfast Symposium State-of-the-Art Advances in T2DM Management: Expert Analysis of New & Emerging GLP-1 Receptor Agonists Thomas Blevins, MD; Anne Peters, MD; Carol Wysham, MD Supported by an educational grant from Lilly USA, LLC 8:00 8:10am Opening Remarks Robert Eckel, MD 8:10 9:00am Keynote Session Brown Fat: Is It Important to Body Weight and Metabolic Risk in Humans? C. Ronald Kahn, MD 9:00 9:30am Metabolic Surgery 2013: Patient Selection and Outcomes Francesco Rubino, MD 9:30 10:00am Look AHEAD: Interpreting the Results for Clinical Practice David Nathan, MD 10:00 10:15am Morning Break 10:15 11:00am Diet & Exercise: What s the Optimal Prescription? moderator: Robert Eckel, MD discussants: I-Min Lee, MD, ScD; Barbara Millen, DrPH, RD 11:00 11:30am Clinical Management of Obesity-Related NAFLD Samuel Klein, MD 11:30 11:50am Obesity Medicine: Practical Pointers for Your Office or Clinic Robert Kushner, MD 11:50am 12:30pm 12:30pm Clinical Challenges & Practical Strategies for Obesity Management moderator: Robert Eckel, MD discussants: C. Ronald Kahn, MD; Samuel Klein, MD; Robert Kushner, MD; I-Min Lee, MD, ScD; Barbara Millen, DrPH, RD; David Nathan, MD; Francesco Rubino, MD Closing Remarks Robert Eckel, MD Agenda and faculty are subject to change. Agenda 21

22 COME VISIT AT BOOTH 301 VASCEPA (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe ( 500 mg/dl) hypertriglyceridemia. Vascepa significantly reduced TG levels without increasing LDL-C 1 Median baseline (mg/dl) Placebo-Adjusted Median Percent Change From Baseline 1,2 TGs % (p<0.001) LDL-C 91-2% (NS) VASCEPA 4 g/day n=76 n The effects of VASCEPA 4 grams per day were assessed in a 12-week, randomized, placebo-controlled, double-blind, parallel-group study evaluating patients with fasting TG levels 500 mg/dl and 2000 mg/dl (with or without statin therapy). 1 n The primary study end point was the placebo-adjusted median percent change in TG levels from baseline. 2 n TGs: VASCEPA, 27% median decrease from baseline; placebo (n=75), 10% increase. n LDL-C: VASCEPA, 5% median decrease from baseline; placebo (n=75), 3% decrease. NS=not significant. Vascepa demonstrated a tolerability and side-effect profile similar to placebo 1,2 The most common adverse event occurring at an incidence >2% and greater than placebo was arthralgia (2.3% for VASCEPA vs 1.0% for placebo)* *Studies included patients with TG levels of 200 to 2000 mg/dl. Limitations of Use for Vascepa The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. The effect of VASCEPA on cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined. VASCEPA is covered on the majority of plans with minimal restrictions. Please see Brief Summary on the inside back cover or for full Prescribing Information for VASCEPA, visit or visit us at booth 301.

23 For the treatment of severe hypertriglyceridemia (triglyceride levels 500 mg/dl) VASCEPA TG Therapy Redefined: VASCEPA significantly reduced TG levels without increasing LDL-C 1 Vascepa significantly improved multiple lipid parameters 1,2 Median baseline (mg/dl) Placebo-Adjusted Median Percent Change From Baseline 1,2 Apo B 121-9% (p<0.05) non HDL-C % (p<0.001) TC % (p<0.001) VLDL-C % (p<0.05) HDL-C 27-4% (NS) n VASCEPA 4 g/day, n=76; placebo, n=75. n Apo B: VASCEPA, 4% median decrease from baseline; placebo, 4% increase. n Non HDL-C: VASCEPA, 8% median decrease from baseline; placebo, 8% increase. n TC: VASCEPA, 7% median decrease from baseline; placebo, 8% increase. n VLDL-C: VASCEPA, 20% median decrease from baseline; placebo, 14% increase. n HDL-C: VASCEPA, 4% median decrease from baseline; placebo, no change. NS=not significant. Vascepa dose is 4 g/day, 2 capsules twice daily with food 1 Important safety Information for Vascepa VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components. Use with caution in patients with known hypersensitivity to fish and/or shellfish. The most common reported adverse reaction (incidence >2% and greater than placebo) was arthralgia. Patients should be advised to swallow VASCEPA capsules whole; not to break open, crush, dissolve, or chew VASCEPA. Adverse events may be reported by calling VASCEPA or the FDA at FDA Apo B=Apolipoprotein B; HDL-C=high-density lipoprotein cholesterol; LDL-C=low-density lipoprotein cholesterol; TC=total cholesterol; VLDL-C=very low-density lipoprotein cholesterol. References: 1. VASCEPA [package insert]. Bedminster, NJ: Amarin Pharma Inc.; Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, placebo-controlled, Randomized, double-blind, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011;108(5): /13

24 VASCEPA (icosapent ethyl) Capsules, for oral use Brief summary of Prescribing Information Please see Full Prescribing Information for additional information about VASCEPA. 1 INDICATIONS AND USAGE VASCEPA (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe ( 500 mg/dl) hypertriglyceridemia. Usage Considerations: Patients should be placed on an appropriate lipid-lowering diet and exercise regimen before receiving VASCEPA and should continue this diet and exercise regimen with VASCEPA. Attempts should be made to control any medical problems such as diabetes mellitus, hypothyroidism, and alcohol intake that may contribute to lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed, if possible, prior to consideration of TG-lowering drug therapy. Limitations of Use: The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. The effect of VASCEPA on cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined. 2 DOSAGE AND ADMINISTRATION Assess lipid levels before initiating therapy. Identify other causes (e.g., diabetes mellitus, hypothyroidism, or medications) of high triglyceride levels and manage as appropriate. [see Indications and Usage (1)]. Patients should engage in appropriate nutritional intake and physical activity before receiving VASCEPA, which should continue during treatment with VASCEPA. The daily dose of VASCEPA is 4 grams per day taken as 2 capsules twice daily with food. Patients should be advised to swallow VASCEPA capsules whole. Do not break open, crush, dissolve, or chew VASCEPA. 4 CONTRAINDICATIONS VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components. 5 WARNINGS AND PRECAUTIONS 5.1 Monitoring: Laboratory Tests In patients with hepatic impairment, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels should be monitored periodically during therapy with VASCEPA. 5.2 Fish Allergy VASCEPA contains ethyl esters of the omega-3 fatty acid, eicosapentaenoic acid (EPA), obtained from the oil of fish. It is not known whether patients with allergies to fish and/or shellfish are at increased risk of an allergic reaction to VASCEPA. VASCEPA should be used with caution in patients with known hypersensitivity to fish and/or shellfish. 6 ADVERSE REACTIONS 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse reactions reported in at least 2% and at a greater rate than placebo for patients treated with VASCEPA based on pooled data across two clinical studies are listed in Table 1. Table 1. Adverse Reactions Occurring at Incidence >2% and Greater than Placebo in Double-Blind, Placebo-Controlled Trials* Placebo VASCEPA (N=309) (N=622) Adverse Reaction n % n % Arthralgia *Studies included patients with triglycerides values of 200 to 2000 mg/dl. An additional adverse reaction from clinical studies was oropharyngeal pain. 7 DRUG INTERACTIONS 7.1 Anticoagulants Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. The prolongation of bleeding time reported in those studies has not exceeded normal limits and did not produce clinically significant bleeding episodes. Patients receiving treatment with VASCEPA and other drugs affecting coagulation (e.g., anti-platelet agents) should be monitored periodically. 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. It is unknown whether VASCEPA can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. VASCEPA should be used during pregnancy only if the potential benefit to the patient justifies the potential risk to the fetus. In pregnant rats given oral gavage doses of 0.3, 1 and 2 g/kg/day icosapent ethyl from gestation through organogenesis all drug treated groups had visceral or skeletal abnormalities including: 13 th reduced ribs, additional liver lobes, testes medially displaced and/or not descended at human systemic exposures following a maximum oral dose of 4 g/day based on body surface comparisons. Variations including incomplete or abnormal ossification of various skeletal bones were observed in the 2 g/kg/day group at 5 times human systemic exposure following an oral dose of 4 g/day based on body surface area comparison. In a multigenerational developmental study in pregnant rats given oral gavage doses of 0.3, 1, 3 g/kg/day ethyl-epa from gestation day 7-17, an increased incidence of absent optic nerves and unilateral testes atrophy were observed at 0.3 g/kg/day at human systemic exposure following an oral dose of 4 g/day based on body surface area comparisons across species. Additional variations consisting of early incisor eruption and increased percent cervical ribs were observed at the same exposures. Pups from high dose treated dams exhibited decreased copulation rates, delayed estrus, decreased implantations and decreased surviving fetuses (F2) suggesting multigenerational effects of ethyl-epa at 7 times human systemic exposure following 4 g/day dose based on body surface area comparisons across species. In pregnant rabbits given oral gavage doses of 0.1, 0.3, and 1 g/kg/day from gestation through organogenesis there were increased dead fetuses at 1 g/kg/day secondary to maternal toxicity (significantly decreased food consumption and body weight loss). In pregnant rats given ethyl-epa from gestation day 17 through lactation day 20 at 0.3, 1, 3 g/kg/day complete litter loss was observed in 2/23 litters at the low dose and 1/23 mid-dose dams by post-natal day 4 at human exposures based on a maximum dose of 4 g/ day comparing body surface areas across species. 8.3 Nursing Mothers Studies with omega-3-acid ethyl esters have demonstrated excretion in human milk. The effect of this excretion is unknown; caution should be exercised when VASCEPA is administered to a nursing mother. In lactating rats, given oral gavage 14 C-ethyl EPA, drug levels were 6 to 14 times higher in milk than in plasma. 8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. 8.5 Geriatric Use Of the total number of subjects in clinical studies of VASCEPA, 33% were 65 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. 9 DRUG ABUSE AND DEPENDENCE VASCEPA does not have any known drug abuse or withdrawal effects. 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility In a 2-year rat carcinogenicity study with oral gavage doses of 0.09, 0.27, and 0.91 g/kg/day icosapent ethyl, respectively, males did not exhibit drug-related neoplasms. Hemangiomas and hemangiosarcomas of the mesenteric lymph node, the site of drug absorption, were observed in females at clinically relevant exposures based on body surface area comparisons across species relative to the maximum clinical dose of 4 g/day. Overall incidence of hemangiomas and hemangiosarcomas in all vascular tissues did not increase with treatment. In a 6-month carcinogenicity study in Tg.rasH2 transgenic mice with oral gavage doses of 0.5, 1, 2, and 4.6 g/kg/day icosapent ethyl, drug-related incidences of benign squamous cell papilloma in the skin and subcutis of the tail was observed in high dose male mice. The papillomas were considered to develop secondary to chronic irritation of the proximal tail associated with fecal excretion of oil and therefore not clinically relevant. Drug-related neoplasms were not observed in female mice. Icosapent ethyl was not mutagenic with or without metabolic activation in the bacterial mutagenesis (Ames) assay or in the in vivo mouse micronucleus assay. A chromosomal aberration assay in Chinese Hamster Ovary (CHO) cells was positive for clastogenicity with and without metabolic activation. In an oral gavage rat fertility study, ethyl-epa, administered at doses of 0.3, 1, and 3 g/kg/day to male rats for 9 weeks before mating and to female rats for 14 days before mating through day 7 of gestation, increased anogenital distance in female pups and increased cervical ribs were observed at 3 g/kg/day (7 times human systemic exposure with 4 g/day clinical dose based on a body surface area comparison). 17 PATIENT COUNSELING INFORMATION 17.1 Information for Patients See VASCEPA Full Package Insert for Patient Counseling Information Distributed by: Amarin Pharma Inc., Bedminster, NJ, USA Manufactured by: Banner Pharmacaps, Tilburg, The Netherlands or Catalent Pharma Solutions, LLC, St. Petersburg, FL, USA Manufactured for: Amarin Pharmaceuticals Ireland Limited, Dublin, Ireland Amarin Pharma Inc. Bedminster, NJ Amarin Pharmaceuticals Ireland Limited All rights reserved /13

25 Industry Supporters & Sponsors The 2013 CMHC gratefully acknowledges the educational grant support and sponsorship provided by the following organizations. Platinum Supporters Gold Supporters Gold Sponsors Silver Sponsors Industry Supporters & Sponsors Bronze Supporter 25

26 Association Supporters The 2013 CMHC gratefully acknowledges our Association Supporters. American Heart Association Councils on High Blood Pressure Research; Stroke; Epidemiology & Prevention; CV Disease in the Young; Basic CV Sciences; Nutrition, Physical Activity & Metabolism; CV Nursing; Clinical Cardiology; Kidney in CV Disease AMERICAN INCORPORATED A.C.N. COLLEGE OF NUTRITION New Jersey Coordinating Body of AADE Association of Physicians Assistants in Cardiology San Francisco Bay Area Association of Diabetes Educators Association Supporters Metropolitan New York Association of Diabetes Educators ECLM EUROPEAN COLLEGE OF PREVENTIVE AND LIFESTYLE MEDICINE 26 For information on becoming a 2014 CMHC Association Supporter, contact CMHC at

27 ipad mini GIVEAWAY Visit each booth in the CMHC Exhibit Hall for a chance to win an ipad Mini! Each booth you have your name badge scanned at will count toward one entry into the raffle. So visit as many booths as you can. Good Luck!! Raffle entry deadline is Friday, October 4 at 5:00pm. Winner to be announced Saturday, October 5 during the General Session.

28 2013 Daiichi Sankyo, Inc. DSNA Printed in USA 08/13

29 Daiichi Sankyo is a global pharmaceutical company with its corporate origin in Japan. We provide innovative products and services in more than 50 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and medical advancements. Building on our experience in hypertension, antiplatelet, and anticoagulation therapies, we are excited to be expanding into other important areas such as oncology, where significant unmet medical needs remain. Today, with our growing presence in developing and emerging markets, we are pleased to serve the needs of patients throughout the world. Discover more at VISIT BOOTH #607 AND LEARN MORE ABOUT HOW OUR PRODUCTS CAN HELP YOUR PATIENTS

30 Exhibit Hall Floor Plan Hynes Convention Center Exhibitors Guide Hours of Operation Thursday, October 3 Friday, October 4 9:30am 12:00pm 9:00am 12:00pm 2:30pm 6:45pm 2:00pm 5:00pm 30 Join us... in the Exhibit Hall for our Welcome Reception Thursday, October 3 5:30pm - 6:30pm

31 Exhibitors Booth Number Aegerion Pharmaceuticals Amarin Pharma Inc Amgen Inc AstraZeneca AstraZeneca/Bristol-Myers Squibb AstraZeneca/Bristol-Myers Squibb Atherotech Diagnostics Lab Bariatrix Nutrition Group BD - Diabetes Care BMIQ Boehringer Ingelheim Pharmaceuticals, Inc/Lilly, USA Boston Heart Diagnostics Daiichi Sankyo, Inc diadexus, Inc Eisai, Inc ETHICON Everidis Health Sciences Forest Pharmaceuticals, Inc Genova Diagnostics Genzyme, A SANOFI COMPANY Gilead Sciences, Inc Health Diagnostic Laboratory, Inc Ideal Protein of America Infinite Therapeutics Janssen Pharmaceuticals, Inc Kaneka Pharma America, LLC Kowa Pharmaceuticals America, Inc LD Technology, LLC LipoScience LipoScience Global Research Services LipoScience Presentation Merck & Co., Inc Novo Nordisk, Inc Otsuka America Pharmaceutical, Inc Pure Encapsulations Santarus, Inc SleepImage Vital Nutrients VIVUS, Inc Exhibitors Guide 31

32 Exhibitors Guide Aegerion Pharmaceuticals Main Street, Suite 1850 Cambridge, MA web: Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating often fatal, rare diseases. Our initial focus is to bring novel therapies to patients with severe lipid disorders. Amarin Pharma Inc Route 206, Suite 200 Bedminster, NJ web: Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa (icosapent ethyl), Amarin s first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA. For more information about Vascepa visit For more information about Amarin visit Amgen Inc One Amgen Center Drive Thousand Oaks, CA web: Amgen, a biotechnology pioneer, discovers, develops, and delivers innovative human therapeutics. Our medicines help millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, we continue to advance science to serve patients. Exhibitors Guide 32 AstraZeneca Steere Road Cumberland, RI tel: web: AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. AstraZeneca/Bristol-Myers Squibb , Scudders Mill Rd. Plainsboro, NJ tel: web: web: Dedicated to addressing the global burden of diabetes by advancing individualized patient care, AstraZeneca and Bristol-Myers Squibb are working in collaboration to research, develop and commercialize a versatile portfolio of innovative treatment options for diabetes and related metabolic disorders.

33 Atherotech Diagnostics Lab London Parkway Birmingham, AL web: Atherotech Diagnostics Lab is a leading clinical reference laboratory specializing in cardiometabolic testing and disease management solutions. Atherotech s proprietary and comprehensive VAP Lipid Panel enables clinicians to accurately stratify a patient s cardiovascular risk and deliver personalized treatment strategies to improve health outcomes. The VAP technology reveals residual risk as recommended in the NCEP ATP III, ADA/ACC Joint Consensus and AACE guidelines. The VAP Lipid Panel utilizes direct measurement to identify cholesterol, triglyceride and genetic lipid disorders. For more information, please visit or call VAP-TEST Bariatrix Nutrition Group Ossipee Rd Newton Upper Falls, MA tel: info@bariatrixgroup.com web: For more than three decades, Bariatrix Nutrition Group has been a trusted leader in the field of professionally directed weight management. We have invested in developing a full suite of products and services to address the most important challenges facing weight loss professionals today. We believe that with our integrated approach, that includes technology-based programs, great-tasting food products and targeted nutraceuticals, patients will lose weight and succeed in adopting new behaviors that lead to sustainable lifestyle change. BD - Diabetes Care One Becton St Franklin Lakes, NJ web: In recent years there has been a major shift toward shorter length needles. Many recommendations that presently exist have little or no underpinning and are based as much on habit and tradition as on evidence. The new evidenced based global injections recommendations provide clear evidence based recommendations for specific populations and stress the need for correct injection technique which is critical for your patient s optimal glycemic control. Learn about the findings of the largest study ever done in adults with diabetes to measure the skin and subcutaneous thickness and their relation to selecting the proper needle length for your patient which enables the initiation and better outcomes of injectable diabetes therapy. BMIQ Veterans Highway Suite 175E Holbrook, NY tel: admin@bmiq.com BMIQ provides evidence-based weight control programs developed by Dr. Louis Aronne. The BMIQ Professionals Program is a turnkey solution that provides health care providers with everything needed to deliver an evidence-based program in their office. Provider-branded web site, personalized accounts, session materials for patients and the professional for 20 visits, online tools and resources provide the perfect complement to office visits. Visit our booth for a system and program overview and see how you can get started today! Exhibitors Guide 33

34 Exhibitors Guide Boehringer Ingelheim Pharmaceuticals, Inc/Lilly, USA Ridgebury Road Ridgefield, CT web: web: Boehringer Ingelheim Pharmaceuticals, Inc., and Lilly USA, LLC welcome you to Cardiometabolic Health Congress (CHMC) and look forward to the opportunity to share the latest clinical information on our products. Visit us at and Boston Heart Diagnostics Crossing Blvd, Suite 100 Framingham, MA web: Boston Heart Diagnostics is a heart health management company providing integrated diagnostic and patient management solutions that are advancing cardiovascular disease risk assessment, monitoring and treatment. Daiichi Sankyo, Inc Hilton Court Parsippany, NJ web: Daiichi Sankyo, Inc. (DSI), headquartered in Parsippany, NJ, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd., a global pharmaceutical company. DSI was formed in 2006 from the integration of two leading pharmaceutical companies, Sankyo Pharma, Inc. and Daiichi Pharmaceutical Corporation. Its team of nearly 3,000 U.S. employees is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients. DSI concentrates in the therapy areas of hypertension, thrombosis, dyslipidemia, diabetes and acute coronary syndrome. Clinical development and regulatory activities are headquartered at Daiichi Sankyo Pharma Development in Edison, NJ. Visit Exhibitors Guide 34 diadexus, Inc Oyster Point Blvd South San Francisco, CA web: diadexus, Inc., is a biotechnology company focused on the development and commercialization of novel in vitro diagnostic tests for cardiovascular disease. The PLAC Test for Lp-PLA2 (lipoprotein-associated phospholipase A2) is a blood test that measures the enzyme activity of Lp-PLA2. Lp-PLA2 is a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. Plaque rupture and thrombosis cause the majority of cardiac events. The PLAC Test helps to identify the patients with hidden CVD risk independent from traditional risk factors. Visit for more information. Eisai, Inc Tice Blvd. Woodcliff Lake, NJ web: Eisai Inc. is the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Headquartered in Woodcliff Lake, New Jersey, Eisai s key areas of commercial focus are neurology and oncology. Eisai s global product creation organization includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, and manufacturing facilities in Maryland and North Carolina. Established in 1995, the company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. For more information about Eisai, please visit

35 ETHICON Creek Road Cincinnati, OH web: Ethicon, Inc. and Ethicon Endo-Surgery, Inc., two companies with long histories of medical innovation, do business under the Ethicon brand. Their surgical technologies and products (including sutures, staplers, clip appliers, trocars and meshes) are used around the world to treat colorectal and thoracic conditions, women s health conditions, hernias, cancer and obesity. Ethicon, Inc. and Ethicon Endo-Surgery, Inc. are part of the Johnson & Johnson Family of Companies. Everidis Health Sciences Brannon Avenue St. Louis, MO tel: web: Everidis is an innovative health sciences company focused on developing unique approaches to address nutritional and metabolic deficiencies. We strive to translate peer-reviewed research on health and nutrition into products that are safe, therapeutic and healthful. We are committed to improving patient quality of life. Forest Pharmaceuticals, Inc Shoreline Drive St. Louis, MO info@forestpharm.com web: Forest s longstanding global partnerships and track record developing and marketing pharmaceutical products in the United States have yielded its well-established central nervous system and cardiovascular franchises and innovations in anti-infective, respiratory, and gastrointestinal medicine. The Company s pipeline, the most robust in its history, includes product candidates in all stages of development across a wide range of therapeutic areas. Genova Diagnostics Zillicoa St. Asheville, NC tel: info@gdx.net web: Headquartered in Asheville, N.C., Genova Diagnostics is a global, specialty clinical laboratory, pioneering a systems approach that supports healthcare providers in the personalized treatment and prevention of chronic disease. Chronic diseases are often complex, and Genova Diagnostic s system-based testing helps physicians develop targeted treatments for their patients. Easy-to-read color graphic reports synthesize test results into actionable information and facilitate better physician-patient communication. The internationally renowned lab is committed to the highest standards and has a robust array of educational resources, as well as a team of medical experts who provide consultation to healthcare practitioners to ensure that physicians order the right tests for their patients. Exhibitors Guide 35

36 Exhibitors Guide Genzyme, A SANOFI COMPANY Kendall Street Cambridge, MA web: Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research, collaboration with the global patient community, and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. Genzyme s portfolio of transformative therapies which are marketed in countries around the world, represent groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at www. genzyme.com. Gilead Sciences, Inc Lakeside Drive Foster City, CA corporate_development@gilead.com web: Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and experimental drug candidate, we seek to improve the care of patients suffering from life-threatening diseases around the world. Gilead s therapeutic areas of focus include HIV/AIDS, hepatitis, serious respiratory, cardiovascular, and metabolic conditions, cancer and inflammation. Exhibitors Guide Health Diagnostic Laboratory, Inc N. 5th Street Richmond, VA web: Health Diagnostic Laboratory, Inc. (HDL, Inc.) is a leader in health management offering a comprehensive test menu of risk factors and biomarkers for cardiovascular disease, diabetes, and related diseases. HDL, Inc. s systematic approach identifies factors contributing to disease and can provide a basis for personalized treatment, allowing physicians to more effectively manage patients. Individuals receive a personalized overview of their risk factors along with intensive counseling from expert Clinical Health Consultants at no additional cost, improving compliance and enhancing satisfaction. HDL, Inc. is a CLIA-certified, CAP-accredited laboratory. Ideal Protein of America Jean-Proulx Gatineau, Québec, Canada J8Z1W1 tel: web: Ideal Protein is a medically designed protocol that contains 2 key components- weight loss and a healthier lifestyle education provided by licensed healthcare professionals. 36

37 Infinite Therapeutics Route 125 Kingston, NH tel: fax: web: The Infinity IT-8800, COMPARABLE TO THE INADA TM for 1/2 the price, offers state of the art roller foot reflexology, thigh and hip massage, an amazing spinal decompression stretch, sensors for customized targeted massage, lumbar heat and music, endless luxury, ULTIMATE MASSAGE! Janssen Pharmaceuticals, Inc Route 202 Raritan, NJ web: Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, provides medicines for an array of health concerns in several therapeutic areas, including: attention deficit hyperactivity disorder (ADHD), general medicine (acid reflux disease, infectious diseases), mental health (bipolar I disorder, schizophrenia), neurologics (Alzheimer s disease, epilepsy, migraine prevention and treatment), pain management, cardiovascular, and women s health. Our ultimate goal is to help people live healthy lives. We have produced and marketed many first-in-class prescription medications and are poised to serve the broad needs of the healthcare market from patients to practitioners, from clinics to hospitals. Kaneka Pharma America, LLC Fifth Avenue New York, NY web: The LIPOSORBER System is indicated for use in performing low density lipoprotein cholesterol (LDL-C) apheresis to acutely remove LDL-C from the plasma of the following high risk patient populations for whom diet has been ineffective and maximum drug therapy has either been ineffective or not tolerated: Patients with LDL-C >300 mg/dl, Patients with LDL-C >200 mg/dl and documented coronary heart disease (CHD). Kowa Pharmaceuticals America, Inc Industrial Park Blvd Montgomery, AL tel: web: Kowa Pharmaceuticals is a specialty pharmaceutical company focused on delivering customer solutions for cardiovascular conditions. Products: Livalo-HMG-CoA reductase inhibitor indicated for patients with primary hyperlipidemia and mixed dyslipidemia. Lipofen fenofibrate capsule: indicated for patients with hypercholesterolemia, mixed dyslipidemia and patients with severe hypertriglyceridemia. Exhibitors Guide 37

38 Exhibitors Guide LD Technology, LLC N Biscayne, Suite 502 Miami, FL web: LLD Technology, LLC is a US medical device manufacturer, that specializes in the design and development of non-invasive, point-of-care biosensors. Our unique product, combining different technologies, assist physician in identifying cardio metabolic risk factors and Autonomic nervous system dysfunction. Features include early detection of diabetes complications (sudomotor function, autonomic neuropathy, cardiovascular disease) and significantly improve diabetes treatment management ( LipoScience Sumner Blvd Raleigh, NC web: LipoScience offers the NMR LipoProfile test. The NMR LipoProfile test measures LDL particle number (LDL-P) and standard lipid parameters to aid in the management of cardiovascular disease using nuclear magnetic resonance (NMR) technology. For more information, please visit www. liposcience.com. LipoScience Global Research Services Sumner Blvd Raleigh, NC tel: fax: djobe@liposcience.com web: LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR). The NMR LipoProfile test, the company s first proprietary test, measures LDL particle number (LDL-P) and standard lipids to aid in the management of cardiovascular disease. For more information, please visit Exhibitors Guide LipoScience Presentation Sumner Blvd Raleigh, NC web: LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The NMR LipoProfile test, measures the number of low density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. For more information, please visit For information regarding 2014 CMHC Exhibit Opportunities, please contact Brittany or Tina or info@cardiometabolichealth.org

39 Merck & Co., Inc One Merck Drive P.O. Box 100 Whitehouse Station, NJ tel: web: Today s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships that donate and deliver our products to the people who need them. For more information, visit Novo Nordisk, Inc College Road West Princeton, NJ tel: web: Novo Nordisk is a health care company with an 88-year history of innovation and achievement in diabetes care. Novo Nordisk is Changing Diabetes by helping to improve diabetes care through partnerships, research, products and services that make a significant difference to patients, the medical professional and society at large. Our portfolio of diabetes pharmaceuticals and delivery systems is the most comprehensive available and now includes the first human glucagon-like peptide 1(GLP-1) analog for the treatment of diabetes. Otsuka America Pharmaceutical, Inc Research Boulevard Rockville, MD web: Otsuka America Pharmaceutical, Inc. (OAPI) is an innovative, fast-growing healthcare company that commercializes Otsuka-discovered and in-licensed products in the U.S. With a strong focus on neuroscience, oncology, cardio-renal and medical device, OAPI is dedicated to improving patient health and the quality of human life. OAPI is part of the Otsuka Group companies. For more information, visit Pure Encapsulations Boston Post Road Sudbury, MA web: Pure Encapsulations is committed to producing the most complete line of science-based nutritional supplements. Available through health professionals, finished products are pure and hypo-allergenic to optimize the long-term health of the most sensitive patients. Pure Encapsulations is NSF-GMP registered in the U.S., GMP certified in Canada and exceeds the standards of the United States Pharmacopeia (USP) for supplement manufacturing.* Distributed worldwide, Pure Encapsulations products contain the highest quality ingredients in their most bioavailable forms and are formulated to provide strengths and dosing consistent with clinical experience and double-blind, placebo-controlled studies, the gold standard of research design. For additional information, please visit our website. Exhibitors Guide 39

40 Exhibitors Guide Santarus, Inc Valley Centre Drive, Suite 400 San Diego, CA tel: fax: web: Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company s current commercial efforts are focused on five products, of which two are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes. SleepImage Interlocken Blvd. Suite 650 Broomfield, CO sales@sleepimage.com web: The SleepImage patient-centered, low cost screening device is the only simple and objective measure of sleep quality. Most home sleep tests only test for sleep apnea, SleepImage tests total sleep health. The SleepImage system offers the first indication of poor sleep, identifying the potential for poor health. At the core of our lightweight, ultra-convenient solution is the proprietary Cardiopulmonary Coupling (CPC) technology. This innovative solution measures sleep quality through breathing and heart rate patterns known to control stable, healthy sleep versus unstable, unhealthy sleep. The SleepImage system offers the only cost effective way to track treatment outcomes over time. Exhibitors Guide Vital Nutrients Kenneth Dooley Drive Middletown, CT orders@vitalnutrients.net web: Vital Nutrients is an American-owned supplement manufacturer that is widely known as The Leader in Quality Assurance. The Vital Nutrients product line includes 200 science-based and pharmaceutical-grade supplements sold exclusively to healthcare professionals. All products are manufactured in the U.S. at an FDA-Inspected facility. Vital NutrientsQuality Assurance program exceeds industry and regulatory standards. Every batch of raw material and finished product is tested at accredited U.S. independent labs, ensuring purity and potency in every bottle. VIVUS, Inc E. Evelyn Ave Mountain View, CA ir@vivus.com web: VIVUS is a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products addressing obesity, diabetes, sleep apnea and sexual health. Qsymia is approved as an adjunct to diet and exercise for chronic weight management in adults who are obese or overweight with at least one weight-related comorbidity. 40

41 Publication Supporters The 2013 CMHC gratefully acknowledges our Publication Supporters. Publication Supporters For information on becoming a 2014 Publication Supporter, contact the CMHC at

42 2013 AstraZeneca Pharmaceuticals LP and Bristol-Myers Squibb Company. Onglyza is a trademark of Bristol-Myers Squibb Company. 466US13BR /13

43 Save the Date! October 22 25, 2014 Boston, MA Exclusive On-Site Registration Offer: Register Today for the 2014 CMHC for Only $195! SAVE UP TO $ 500 The Lowest Rate for the 2014 CMHC! 43

44 COME VISIT AT BOOTH 301 For the treatment of severe hypertriglyceridemia (triglyceride levels 500 mg/dl) VASCEPA TG Therapy Redefined: VASCEPA significantly reduced TG levels without increasing LDL-C 1 Indication and Limitations of Use for Vascepa VASCEPA (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe ( 500 mg/dl) hypertriglyceridemia. The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. The effect of VASCEPA on cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined. Important safety Information for Vascepa VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components. Use with caution in patients with known hypersensitivity to fish and/or shellfish. The most common reported adverse reaction (incidence >2% and greater than placebo) was arthralgia. Patients should be advised to swallow VASCEPA capsules whole; not to break open, crush, dissolve, or chew VASCEPA. Adverse events may be reported by calling VASCEPA or the FDA at FDA Please see full Prescribing Information at or visit VASCEPA at booth 301. Reference: 1. VASCEPA [package insert]. Bedminster, NJ: Amarin Pharma Inc.; Amarin Pharma Inc. Bedminster, NJ Amarin Pharmaceuticals Ireland Limited All rights reserved /13